-

Goldfinch Bio to Present at the 2022 Wedbush PacGrow Healthcare Virtual Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Goldfinch Bio, a clinical stage biotechnology company focused on discovering and developing precision medicines for the treatment of kidney diseases, today announced that Anthony Johnson, M.D., President and Chief Executive Officer of Goldfinch Bio, will participate in a panel discussion, Casino Re-nal – Novel Mechanisms in Renal Disorders, at the Wedbush PacGrow Healthcare Virtual Conference on Tuesday, August 9, 2022 at 3:30 p.m. ET.

About Goldfinch Bio

Goldfinch Bio, Inc. is a clinical stage biotechnology company focused on delivering disease-modifying precision medicines that bring hope and renewed quality of life to people living with kidney diseases. We aspire to save kidneys and end dialysis by applying precision medicine to pioneer the discovery, development and commercialization of kidney disease treatments. Our lead program, GFB-887, is a precision-based podocyte-targeting small molecule inhibitor of TRPC5, which has demonstrated clinical proof-of-concept as a novel treatment of focal segmental glomerulosclerosis. Visit us at www.goldfinchbio.com to learn more.

Contacts

Goldfinch Bio:

Investors:
Hannah Deresiewicz
Stern Investor Relations, Inc.
212-362-1200
hannah.deresiewicz@sternir.com

Media:
Liz Melone
lmelone@goldfinchbio.com

Industry:

Goldfinch Bio, Inc.

Release Versions
English

Contacts

Goldfinch Bio:

Investors:
Hannah Deresiewicz
Stern Investor Relations, Inc.
212-362-1200
hannah.deresiewicz@sternir.com

Media:
Liz Melone
lmelone@goldfinchbio.com

More News From Goldfinch Bio, Inc.

Goldfinch Bio Announces Publication in Science Advances on the Validation of Human Derived Organoids as a Predictable and Translatable Preclinical Model in Kidney Disease for the Evaluation of Therapeutic Drug Candidates

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Goldfinch Bio, Inc., a clinical stage biotechnology company focused on discovering and developing precision medicines for the treatment of kidney diseases, today announced the publication of data validating transplanted, perfused human kidney organoids as a novel, predictive and translatable preclinical PD model for use in kidney disease drug development. This breakthrough approach was initially validated with the company’s lead drug candidate, GFB-887, a sele...

Goldfinch Bio to Present Initial Data from Phase 1 Clinical Trial of GFB-024 at American Diabetes Association 82nd Scientific Sessions and Endocrine Society’s Annual Meeting, ENDO 2022

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Goldfinch Bio, a clinical stage biotechnology company focused on discovering and developing precision medicines for the treatment of kidney diseases, today announced that it will present initial data from its Phase 1 clinical trial of GFB-024 in a poster presentation at the American Diabetes Association (ADA) 82nd Scientific Sessions, taking place June 3-7 in New Orleans, LA, and an oral presentation at the Endocrine Society’s Annual Meeting, ENDO 2022, taking...

Goldfinch Bio to Host Virtual Event on Unmet Need in Focal Segmental Glomerulosclerosis (FSGS) and GFB-887 as a Novel Kidney Precision Medicine Candidate

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Goldfinch Bio, a clinical stage biotechnology company focused on discovering and developing precision medicines for the treatment of kidney diseases, today announced that it will host a virtual event to discuss the unmet need in focal segmental glomerular sclerosis (FSGS), as well as the recently announced clinical data from TRACTION-2, the ongoing Phase 2 trial evaluating GFB-887 as a precision medicine for the treatment of FSGS. GFB-887 is a podocyte-targeti...
Back to Newsroom